In Brief: Pharmacyclics
Pharmacyclics: Withdraws registration for a 2 mil. share public offering, Sunnyvale, Calif.-based Pharmacyclics announces Aug. 22. "We are not willing to raise equity capital at the current valuation," Pharmacyclics declares. Pharmacyclics' June 14 registration statement with the SEC assumes a per-share price of $18.25 for the offering; the stock closed Aug. 21 at $11.25...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth